Glycogen synthase is post-translationally modified by both phosphate and O-linked Nacetylglucosamine (O-GlcNAc). In 3T3-L1 adipocytes exposed to high concentrations of glucose, O-GlcNAc contributes to insulin resistance of glycogen synthase. We sought to determine if O-GlcNAc also regulates glycogen synthase in vivo. Glycogen synthase activity in fat pad extracts was inhibited in streptozotocin (STZ)-treated diabetic mice.
glucose concentrations were measured daily in random fed animals. The STZ treatment resulted in 72% of the mice developing hyperglycemia (resting blood glucose > 13.9 mM) after 8.7 ± 0.5 days. After at least 3 days of hyperglycemia, the mice were weighed, resting blood glucose levels were measured and STZ-treated and control mice were treated with 0.75 units insulin per kg body weight or the equivalent volume of saline.
The mice were then left without food for 60 min, at which time the blood glucose levels were measured, serum collected and both groups of animals sacrificed by cervical dislocation. The animals were immediately dissected, organs frozen in liquid nitrogen and stored at -80˚C. Insulin levels were measured in serum using the Sensitive Rat Insulin RIA kit (Linco Research, Inc., St. Charles, MO). The Institutional Animal Care and Use Committee of the University of Utah and Salt Lake City VA approved all procedures.
Preparation of epididymal fat pad extract. Frozen epididymal fat pads were finely diced with a razor and placed in 1 ml of ice cold buffer containing: 25 mM HEPES 7.4, 100 mM NaCl, 5% glycerol (v/v) and protease inhibitors. They were then immediately homogenized with a Polytron PT 2100 and PT-DA 2107/2EC probe (setting 26 for 15 sec; Kinematica AG, Littau, Switzerland), and centrifuged at 20 000 g for 2 min at 4˚C.
The infranatant was aspirated, frozen as aliquots in liquid nitrogen and stored at -80˚C.
Analysis of glycogen synthase. Glycogen synthase activity was measured as reported previously (18) . Basal glycogen synthase activity (%I-form) was defined as the percentage enzyme activity in the absence of G6P relative to activity in 10 mM G6P. The glycosylated form of glycogen synthase was quantified by binding the glycosylated proteins to immobilized succinylated wheat germ agglutinin, followed by SDS-PAGE and staining the blot with anti-glycogen synthase as described previously (18) .
Phosphorylated glycogen synthase was measured by staining an immunoblot of fat pad extracts with an antibody specific for phosphorylation at the Ser-640 residue of glycogen synthase. Densitometry was conducted as described (18) .
Digestion with jack bean β-D-N-acetylglucosaminidase and protein phosphatase 1.
Epididymal fat pad extract (13.5 µg) was digested at 30˚C in a total of 50 µl in 50 mM acetamido-1-amino-1,2-dideoxy-β-D-glucopyranose, 1 mg/ml bovine serum albumin fraction V and 1% (v/v) protein phosphatase 1 inhibitor cocktail (Sigma), were added to stop the digestion. Duplicate glycogen synthase assays, with and without 10 mM G6P, were then conducted for 30 min at 37˚C as described (18) . A stock of PP1 was prepared by resuspension at a concentration of 7 units/µl in a 50% (v/v) mixture of the desalting buffer and glycerol, and stored as aliquots at -80˚C. To confirm that the conditions described above resulted in deglycosylation and dephosphorylation of glycogen synthase 400 µg of protein was treated under the same conditions with 30 units of β-D-N-acetylglucosaminidase or 6 units of protein phosphatase 1. The incubation was terminated by addition of 750 µl of RIPA buffer.
Endogenous β-D-N-acetylglucosaminidase activity was inhibited by prior addition of 1 mM 2-acetamido-1-amino-1,2-dideoxy-β-D-glucopyranose unless a β-D-Nacetylglucosaminidase digestion was conducted, in which case it was added after the digestion. The glycosylation of glycogen synthase and phosphorylation were measured as described previously (18) . 
Statistical analysis. Significance was determined by using the Students t-test (Microsoft

Results
Characterization of STZ-diabetic mice. We followed a protocol of low-dose STZ treatment to induce moderate hyperglycemia with only mild hypoinsulinemia. STZtreated mice ( Figure 1A ) had an elevation in blood glucose to 20.5 ± 1.2 mM compared to 7.9 ± 0.6 mM in control mice (p < 0.001). Serum insulin levels of the STZ-treated mice (0.8 ± 0.2 ng/ml) tended to be lower than control mice (1.1 ± 0.3 ng/ml), but this difference was not significant ( Figure 1B ). When treated with an intraperitoneal injection of 0.75 units of insulin/kg body weight (20) , serum insulin values increased after 60 min to similar levels of 1.8 ± 0.6 ng/ml in STZ-treated animals and 1.5 ± 0.3 ng/ml in control animals ( Figure 1B ; p = 0.55). Glucose levels were reduced with insulin treatment to 2.4 ± 0.3 mM in controls ( Figure 1A ; p < 0.001). STZ-treated mice were hyperglycemic even after insulin treatment with glucose decreasing only to 14.9 ± 4.3 mM (p=0.07), 6.0-fold more than control mice (p<0.01).
Glycogen synthase from adipose tissue is inhibited in hyperglycemic conditions, even
after exogenous insulin treatment. We next sought to determine the relative roles of glycemia and insulin levels on regulation of glycogen synthase in this mouse model of diabetes. Extracts were made from the epididymal fat pads of control and STZ-treated mice, and control and STZ-treated mice that had been treated with insulin 60 min prior to sacrifice. Glycogen synthase activity was measured over a range of 0 to 10 mM G6P to measure the half-maximal activation concentration for G6P (A 0.5 ) and basal activity (%I-form). Glycogen synthase from the epididymal fat pads of STZ-treated mice was inhibited, with the A 0.5 value increasing from 240 ± 20 µM G6P in fat pad extracts of The phosphorylation of glycogen synthase is the same in both hyperglycemic and control mice. We next determined whether the inhibition of glycogen synthase in the hyperglycemic mice could be explained by increased phosphorylation of the enzyme.
Epididymal fat pad extracts from control and diabetic mice, treated with and without insulin, were resolved by SDS/PAGE, immunostained with an antibody specific for a key regulatory phosphorylation site (Ser-640) on glycogen synthase and quantified with densitometry ( Figure 3A with the blood glucose levels that were measured prior to insulin treatment (A 0.5 , r 2 =0.49, p < 0.005; %I-form, r 2 = 0.27, p < 0.05; data not shown). control, 100 ± 10% and STZ-treated 310 ± 70%). Phosphatase digestion did not change the glycosylation status of the enzyme.
Glycogen synthase is differentially modified by O-GlcNAc in
In mice that were not treated with insulin the absolute increase in basal glycogen synthase activity seen after digestion with PP1 plus β-D-N-acetylglucosaminidase, compared to PP1 treatment alone, correlated significantly with blood glucose concentrations (r 2 =0.98, p < 0.005; Figure 6C ). The correlation, however, was eliminated with insulin treatment. The K m value of OGT for UDP-N-acetylglucosamine is relatively high (33) . Thus, high levels of O-GlcNAc on nuclear and cytoplasmic proteins reflect a high level of nutrient uptake (32, 34) . This makes O-GlcNAc an attractive candidate for a nutrient sensing mechanism and for mediating the cellular consequences of excess nutrient flux (34-37). Glycogen synthase has been previously regarded as being primarily regulated by phosphorylation-dephosphorylation and allosteric activation by G6P. These factors are interdependent: increased phosphorylation reduces sensitivity G6P, but G6P changes the conformation of the protein to simultaneously activate the enzyme and make it a better substrate for dephosphorylation (4, 23, 48, 49) . In diabetes this regulation breaks down and glycogen synthase is inhibited and less responsive to insulin activation, even though G6P levels are unchanged (9,10,22,50-52). In some situations this may be partly attributable to upstream effects of the hexosamine pathway on signal transduction elements such as PI3 kinase, IRS-1 or β-catenin (26, 27, 30, (53) (54) (55) . However, in studies on glycogen synthase from the livers of STZ-treated rats, diabetes also directly inhibited the ability of by guest on November 6, 2017
